These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

812 related articles for article (PubMed ID: 19447413)

  • 21. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy.
    Sonpavde G; Khan MM; Svatek RS; Lee R; Novara G; Tilki D; Lerner SP; Amiel GE; Skinner E; Karakiewicz PI; Bastian PJ; Kassouf W; Fritsche HM; Izawa JI; Ficarra V; Dinney CP; Lotan Y; Fradet Y; Shariat SF
    BJU Int; 2011 Sep; 108(5):687-92. PubMed ID: 21087453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy.
    Mills RD; Turner WH; Fleischmann A; Markwalder R; Thalmann GN; Studer UE
    J Urol; 2001 Jul; 166(1):19-23. PubMed ID: 11435814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hospital lymph node counts and survival after radical cystectomy.
    Hollenbeck BK; Ye Z; Wong SL; Montie JE; Birkmeyer JD
    Cancer; 2008 Feb; 112(4):806-12. PubMed ID: 18085612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer.
    Sonpavde G; Khan MM; Lerner SP; Svatek RS; Novara G; Karakiewicz PI; Skinner E; Tilki D; Kassouf W; Fradet Y; Dinney CP; Fritsche HM; Izawa JI; Bastian PJ; Ficarra V; Schoenberg M; Sagalowsky AI; Lotan Y; Shariat SF
    J Urol; 2011 Feb; 185(2):456-61. PubMed ID: 21167527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy.
    May M; Herrmann E; Bolenz C; Brookman-May S; Tiemann A; Moritz R; Fritsche HM; Burger M; Trojan L; Michel MS; Wülfing C; Müller SC; Ellinger J; Buchner A; Stief CG; Tilki D; Wieland WF; Gilfrich C; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Bastian PJ
    Ann Surg Oncol; 2011 Jul; 18(7):2018-25. PubMed ID: 21246405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
    Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
    Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer.
    Isbarn H; Karakiewicz PI; Shariat SF; Capitanio U; Palapattu GS; Sagalowsky AI; Lotan Y; Schoenberg MP; Amiel GE; Lerner SP; Sonpavde G
    J Urol; 2009 Aug; 182(2):459-65; discussion 465. PubMed ID: 19524971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The risk factor for urethral recurrence after radical cystectomy in patients with transitional cell carcinoma of the bladder.
    Cho KS; Seo JW; Park SJ; Lee YH; Choi YD; Cho NH; Yang SC; Hong SJ
    Urol Int; 2009; 82(3):306-11. PubMed ID: 19440019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgical factors influence bladder cancer outcomes: a cooperative group report.
    Herr HW; Faulkner JR; Grossman HB; Natale RB; deVere White R; Sarosdy MF; Crawford ED
    J Clin Oncol; 2004 Jul; 22(14):2781-9. PubMed ID: 15199091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer.
    Margel D; Tal R; Baniel J
    J Urol; 2007 Dec; 178(6):2297-300; discussion 2300-1. PubMed ID: 17936837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy.
    Wright JL; Lin DW; Porter MP
    Cancer; 2008 Jun; 112(11):2401-8. PubMed ID: 18383515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.
    Karakiewicz PI; Shariat SF; Palapattu GS; Gilad AE; Lotan Y; Rogers CG; Vazina A; Gupta A; Bastian PJ; Perrotte P; Sagalowsky AI; Schoenberg M; Lerner SP
    J Urol; 2006 Oct; 176(4 Pt 1):1354-61; discussion 1361-2. PubMed ID: 16952631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary invasive versus progressive invasive transitional cell bladder cancer: multicentric study of overall survival rate.
    Ferreira U; Matheus WE; Nardi Pedro R; Levi D'Ancona CA; Reis LO; Stopiglia RM; Denardi F; Rodrigues Netto N; de Cássio Zequi S; da Fonseca FP; Lopes A; Cardoso Guimarães G; de Carvalho Fernandes R; Cardenuto Perez MD
    Urol Int; 2007; 79(3):200-3. PubMed ID: 17940350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center.
    Kotwal S; Choudhury A; Johnston C; Paul AB; Whelan P; Kiltie AE
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):456-63. PubMed ID: 17904301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer.
    Stein JP; Penson DF; Lee C; Cai J; Miranda G; Skinner DG
    J Urol; 2009 May; 181(5):2052-8; discussion 2058-9. PubMed ID: 19286213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The predictors of local recurrence after radical cystectomy in patients with invasive bladder cancer.
    Ide H; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Nakashima J; Oya M
    Jpn J Clin Oncol; 2008 May; 38(5):360-4. PubMed ID: 18490370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program.
    Konety BR; Joslyn SA
    J Urol; 2003 Nov; 170(5):1765-71. PubMed ID: 14532772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder.
    May M; Nitzke T; Helke C; Vogler H; Hoschke B
    Scand J Urol Nephrol; 2004; 38(3):231-5. PubMed ID: 15204377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.